Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: Effect on lipid profiles

Georg Behrens, Renato Maserati, Armin Rieger, Pere Domingo, Florian Abel, Hui Wang, Gill Pearce

Research output: Contribution to journalArticlepeer-review

Abstract

Background: The aim of this study was to investigate the effect on fasting lipid parameters of switching to tenofovir disoproxil fumarate (TDF) plus emtricitabine (FTC) from abacavir (ABC) plus lamivudine (3TC; both fixeddose combinations), while maintaining ritonavir-boosted lopinavir (LPV/r). Methods: This was an open-label randomized two-arm 12-week controlled study in virologically suppressed HIV-infected patients with elevated cholesterol (≥5.2 mmol/l). Patients stable on ABC/3TC plus LPV/r either continued treatment or switched to TDF/FTC plus LPV/r for 12 weeks. Standard efficacy and safety end points (including fasting lipids) were assessed. Results: In total, 85 subjects were treated (n=42 ABC/FTC and n=43 TDF/3TC). A statistically significant decrease in total cholesterol was observed in the TDF/FTC group: from median (IQR) 6.22 mmol/l (5.91-6.77) at baseline to 5.75 mmol/l (5.04-6.18) at week 12 (median [IQR] change from baseline -0.73 mmol/l [-1.20-0.18]; P

Original languageEnglish
Pages (from-to)1011-1020
Number of pages10
JournalAntiviral Therapy
Volume17
Issue number6
DOIs
Publication statusPublished - 2012

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: Effect on lipid profiles'. Together they form a unique fingerprint.

Cite this